Drug Profile
Research programme: epidermolysis bullosa gene therapies - Abeona Therapeutics
Alternative Names: AAV DJCOL7A1; EB-201Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Abeona Therapeutics
- Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
- Class Gene therapies
- Mechanism of Action Collagen type VII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epidermolysis bullosa